Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One TNF Inhibitor

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One TNF Inhibitor

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPAL-BEYOND
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Jul 2019 Results of pharmacokinetics pooled analysis from two trials (NCT01877668 and NCT01882439) published in the International Journal of Clinical Pharmacology and Therapeutics
    • 15 Jun 2019 Pooled analysis results from OPAL Broaden and OPAL Beyond presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 15 Jun 2019 Results (n=354) of post-hoc analysis of two phase 3 studies (OPAL Broaden and OPAL Beyond) assessing tofacitinib treatment in improvement of pain in psoriatic arthritis patients, presented at the 20th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top